Evie Ring (and EvieMED) vs Samsung Galaxy Ring in 2026

Evie Ring (and EvieMED)

Movano Health's Evie Ring is a women's-health-focused smart ring (menstrual-cycle tracking, sleep, energy, heart rate, SpO2, and mood and goal trends; general-wellness, not a diagnostic) and the lifecycle-state-paused archetype of DEPLOY's biometric ring sub-cohort. The verified-vs-claimed distinction is critical: Evie Ring sales are PAUSED, not discontinued.

Following Movano Health's Corvex reverse merger (closed March 19, 2026), an AI-infrastructure pivot, and a 1-for-10 reverse split, the company paused Evie Ring sales while a divestiture of its EvieMED clinical line is pending. EvieMED (the B2B/clinical variant) is an FDA 510(k)-cleared pulse oximeter and heart-rate device (December 2, 2024) for clinical trials, remote patient monitoring, and payors and pharma.

DEPLOY records the consumer Evie Ring at paused availability with no current retail price. Aggregators routinely flatten this as 'Movano discontinued the Evie Ring'; the accurate state is sales-paused amid a corporate pivot, with the EvieMED divestiture pending (an intention where not yet closed). Movano Health trades as NASDAQ: MOVE (CEO John Mastrototaro).

Samsung Galaxy Ring

The Samsung Galaxy Ring is available for purchase directly from Samsung's website with a Buy Now button; a sizing kit is offered for customers who do not know their ring size. The Samsung Galaxy Ring is priced from $299.99 USD before trade-in, with up to $150 instant trade-in credit available; financing is offered through Affirm at 0 to 36 percent APR.